AOA

AOA

Private
Denver, ColoradoHealthcare & Life Scienceswww.aoadx.com

Last Round

Series A

Oct 12, 2023

Total Funding Raised

$24.08M

Company Overview

AOA Dx is a healthcare technology company that develops an AI-enabled platform for early cancer detection through a liquid biopsy testing kit that analyzes tumor marker gangliosides.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical Devices, Precision Medicine, Clinical Trials, Healthcare Analytics

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

liquid biopsyovarian cancer detectionearly cancer detectiondiagnostic blood testwomen's health diagnosticsFemTechmulti-omicscancer diagnosticsmolecular diagnosticsganglioside biomarkersAKRIVIS GDmachine learning diagnostics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

AOA Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

AOA Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series AOct 12, 2023
SeedSep 13, 2022
SeedJun 28, 2021
GrantMay 20, 2021

Key People

Founding team and executive leadership

Alexander Fisher

COO Co-Founder

Founding Team

Anna Milik Jeter

Chief Regulatory Officer And Co-founder

Founding Team

Oriana Papin-Zoghbi

CEO Co-Founder

Founding Team

victor ramirez

AOA Dx Chief Operating Officer

Executive Team

AOA Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 1, 2026

    Developing AKRIVIS GD™, an early-stage diagnostic for ovarian cancer.

  • Oct 1, 2025

    Introduced GlycoLocate™ for early cancer detection.

AOA Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

AOA Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about AOA's valuation, stock price, and market status.

Firmographic Details

HeadquartersDenver, Colorado
Employee Range56
Year Founded2019
Last FundingOct 12, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.